Celyad Oncology SA (NASDAQ:CYAD – Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.69 and traded as high as $0.81. Celyad Oncology shares last traded at $0.75, with a volume of 8,985 shares. Celyad Oncology Stock Down 5.1 […]
Celyad Oncology (NASDAQ:CYAD – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.25 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 7.66% from the company’s […]
(1)
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively
Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x10
9 cells per infusion
Emergence of new T cell clones in the peripheral blood T cell repertoire four months after therapy was observed in patients analyzed from the highest dose level who experienced either a confirmed partial response or stable disease suggesting that modulation of the endogenous immune response may be an important mechanism of action of CYAD-101 in mCRC patients